AMPH strategy targets BAQSIMI and pipeline launches through 2026
AMPH management outlined a branded and complex generics strategy, citing BAQSIMI and new pipeline launches for mid to high single-digit revenue growth through 2026. Operational improvements and targeted R&D investments are expected to support margin expansion.
Management said its strategy is centered on branded and complex generics, with BAQSIMI and new pipeline launches expected to drive mid to high single-digit revenue growth through 2026. The company said operational improvements and targeted R&D investment are expected to support margin expansion and longer-term growth.